X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5700) 5700
Newsletter (55) 55
Magazine Article (9) 9
Book Chapter (5) 5
Dissertation (2) 2
Newspaper Article (2) 2
Publication (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4166) 4166
male (2850) 2850
female (2410) 2410
thiophenes - administration & dosage (2282) 2282
thiophenes - therapeutic use (2197) 2197
animals (1906) 1906
thiophenes - pharmacology (1709) 1709
middle aged (1532) 1532
aged (1281) 1281
thiophenes - adverse effects (1262) 1262
pharmacology & pharmacy (1150) 1150
adult (1094) 1094
treatment outcome (987) 987
rats (886) 886
rivaroxaban (864) 864
administration, oral (808) 808
dose-response relationship, drug (727) 727
mice (628) 628
double-blind (574) 574
duloxetine hydrochloride (570) 570
double-blind method (563) 563
thiophenes - pharmacokinetics (544) 544
prasugrel hydrochloride (502) 502
drug therapy (471) 471
morpholines - therapeutic use (460) 460
dabigatran (459) 459
morpholines - administration & dosage (438) 438
time factors (415) 415
anticoagulants - therapeutic use (412) 412
drug therapy, combination (409) 409
anticoagulants - administration & dosage (404) 404
aged, 80 and over (402) 402
analysis (391) 391
sulfonamides - administration & dosage (386) 386
ticlopidine - analogs & derivatives (383) 383
efficacy (379) 379
drug administration schedule (373) 373
cardiac & cardiovascular systems (369) 369
medicine & public health (354) 354
safety (354) 354
abridged index medicus (347) 347
neurosciences (345) 345
care and treatment (342) 342
intraocular pressure - drug effects (341) 341
beta-alanine - analogs & derivatives (337) 337
medicine, general & internal (333) 333
anticoagulants (328) 328
oncology (328) 328
thiophene (324) 324
morpholines - adverse effects (320) 320
clopidogrel (317) 317
pharmacokinetics (316) 316
research (315) 315
hematology (314) 314
rats, sprague-dawley (313) 313
anticoagulants - adverse effects (312) 312
ophthalmology (310) 310
duloxetine (305) 305
peripheral vascular disease (303) 303
prevention (302) 302
risk factors (290) 290
thiophenes - chemistry (282) 282
piperazines - administration & dosage (277) 277
randomized controlled trials as topic (272) 272
adolescent (271) 271
piperazines - therapeutic use (269) 269
sulfonamides - therapeutic use (267) 267
venous thromboembolism (264) 264
prasugrel (263) 263
benzimidazoles - therapeutic use (260) 260
disease models, animal (260) 260
prospective studies (260) 260
clinical trials as topic (259) 259
thiophenes (259) 259
clinical neurology (257) 257
psychiatry (248) 248
internal medicine (247) 247
warfarin (247) 247
drug interactions (244) 244
hemorrhage - chemically induced (244) 244
young adult (240) 240
endocrinology & metabolism (239) 239
platelet aggregation inhibitors - therapeutic use (237) 237
therapy (237) 237
factor xa inhibitors (234) 234
rats, wistar (229) 229
administration, topical (227) 227
platelet aggregation inhibitors - administration & dosage (225) 225
pyrazoles - therapeutic use (220) 220
stroke - prevention & control (220) 220
sulfonamides - pharmacology (214) 214
pharmacology (213) 213
risk (212) 212
dosage and administration (211) 211
clinical trials (210) 210
health aspects (209) 209
atrial fibrillation - drug therapy (207) 207
pyridones - therapeutic use (207) 207
pharmacology/toxicology (206) 206
carbonic anhydrase inhibitors - administration & dosage (203) 203
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5410) 5410
German (121) 121
Japanese (77) 77
French (67) 67
Spanish (38) 38
Russian (36) 36
Italian (17) 17
Chinese (12) 12
Hungarian (10) 10
Czech (8) 8
Polish (8) 8
Romanian (7) 7
Slovak (7) 7
Portuguese (5) 5
Danish (4) 4
Croatian (3) 3
Dutch (3) 3
Finnish (2) 2
Norwegian (2) 2
Swedish (2) 2
Arabic (1) 1
Hebrew (1) 1
Lithuanian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the American College of Cardiology, ISSN 0735-1097, 2014, Volume 64, Issue 11, pp. 1128 - 1139
Abstract Background Non–vitamin K oral anticoagulants (NOACs) do not require routine laboratory monitoring. However, laboratory measurement may be desirable in... 
Cardiovascular | Internal Medicine | dabigatran | rivaroxaban | monitoring | laboratory | apixaban | MEASURING RIVAROXABAN | CARDIAC & CARDIOVASCULAR SYSTEMS | DIRECT THROMBIN INHIBITOR | DABIGATRAN CONCENTRATIONS | PROTHROMBIN TIME | PARTIAL THROMBOPLASTIN TIME | COAGULATION ASSAYS | IN-VITRO | FACTOR-XA INHIBITOR | PLASMA-CONCENTRATIONS | INTERNATIONAL NORMALIZED RATIO | Anticoagulants - administration & dosage | Humans | Antithrombins - administration & dosage | Thiophenes - administration & dosage | Dabigatran | Factor Xa Inhibitors - administration & dosage | Antithrombins - pharmacology | Pyridones - administration & dosage | Rivaroxaban | Benzimidazoles - administration & dosage | beta-Alanine - pharmacology | Factor Xa Inhibitors - pharmacology | beta-Alanine - analogs & derivatives | Pyrazoles - pharmacology | Administration, Oral | Morpholines - administration & dosage | beta-Alanine - administration & dosage | Morpholines - pharmacology | Thiophenes - pharmacology | Pyrazoles - administration & dosage | Partial Thromboplastin Time | Anticoagulants - pharmacology | Benzimidazoles - pharmacology | Drug Monitoring | Pyridones - pharmacology | Measurement | Anticoagulants (Medicine) | Vitamins | Studies | Anticoagulants | Plasma | Bibliographic literature | Laboratories | Drug therapy | Drug dosages | Bone surgery
Journal Article
BMC Musculoskeletal Disorders, ISSN 1471-2474, 2008, Volume 9, Issue 1, pp. 165 - 165
Background: Symptomatic slow-acting drugs (SYSADOA) have been largely studied over the last decade. The objective of this study is to prepare a document... 
CHONDROITIN SULFATE | OF-RHEUMATOLOGY RECOMMENDATIONS | INTRAARTICULAR HYALURONIC-ACID | EULAR-STANDING-COMMITTEE | TASK-FORCE | GLUCOSAMINE SULFATE | HIP OSTEOARTHRITIS | DOUBLE-BLIND | RHEUMATOLOGY | ORTHOPEDICS | KNEE OSTEOARTHRITIS | AVOCADO/SOYBEAN UNSAPONIFIABLES | Outcome Assessment (Health Care) - methods | Clinical Trials as Topic - statistics & numerical data | Thiophenes - adverse effects | Antirheumatic Agents - administration & dosage | Humans | Anthraquinones - administration & dosage | Thiophenes - administration & dosage | Osteoarthritis - drug therapy | Calcitonin - administration & dosage | Plant Extracts - administration & dosage | Glucosamine - adverse effects | Chondroitin Sulfates - adverse effects | Anthraquinones - adverse effects | Etidronic Acid - adverse effects | Calcitonin - adverse effects | Antirheumatic Agents - adverse effects | Risedronate Sodium | Hyaluronic Acid - adverse effects | Etidronic Acid - analogs & derivatives | Etidronic Acid - administration & dosage | Hyaluronic Acid - administration & dosage | Organometallic Compounds - adverse effects | Glucosamine - administration & dosage | Chondroitin Sulfates - administration & dosage | Organometallic Compounds - administration & dosage | Plant Extracts - adverse effects | Glucosamine | Research | Hyaluronic acid | Drug therapy | Osteoarthritis | Chondroitin | Index Medicus
Journal Article
International Journal of Cardiology, ISSN 0167-5273, 2014, Volume 179, pp. 279 - 287
Journal Article
British journal of clinical pharmacology, ISSN 0306-5251, 2013, Volume 76, Issue 3, pp. 455 - 466
.../2J2 , P ‐gp and Bcrp ( ABCG2 ). However, the pharmacokinetic effects and implications of the co‐administration of rivaroxaban and medications that interfere... 
P‐glycoprotein | rivaroxaban | drug interactions | cytochrome P450 | healthy subjects | P-glycoprotein | Rivaroxaban | Healthy subjects | Cytochrome P450 | Drug interactions | BAY-59-7939 | SAFETY | PREVENTION | PHARMACODYNAMICS | PROTEASE INHIBITORS | IN-VITRO | FACTOR-XA INHIBITOR | ERYTHROMYCIN | PHARMACOLOGY & PHARMACY | LIVER-MICROSOMES | Anticoagulants - administration & dosage | Cytochrome P-450 Enzyme Inhibitors | Erythromycin - pharmacology | Ketoconazole - administration & dosage | Humans | Middle Aged | Cytochrome P-450 Enzyme System - metabolism | Midazolam - administration & dosage | Substrate Specificity | Metabolic Clearance Rate | Thiophenes - administration & dosage | Ketoconazole - pharmacology | Enzyme Inhibitors - administration & dosage | Young Adult | Drug Interactions | Enzyme Inhibitors - pharmacokinetics | Clarithromycin - pharmacokinetics | Clarithromycin - administration & dosage | Adult | Morpholines - administration & dosage | Enzyme Inhibitors - pharmacology | Ketoconazole - pharmacokinetics | Midazolam - pharmacokinetics | Cytochrome P-450 CYP3A - administration & dosage | Erythromycin - administration & dosage | ATP Binding Cassette Transporter, Subfamily B, Member 1 - antagonists & inhibitors | ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism | Thiophenes - pharmacokinetics | Erythromycin - pharmacokinetics | Cytochrome P-450 CYP3A - metabolism | Adolescent | Anticoagulants - pharmacokinetics | Morpholines - pharmacokinetics | Clarithromycin - pharmacology | Midazolam - pharmacology | Ketoconazole | Protease inhibitors | Fluconazole | Proteases | Cytochrome P-450 | Dosage and administration | Anticoagulants (Medicine) | Erythromycin | Thromboembolism
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2008, Volume 372, Issue 9632, pp. 31 - 39
Summary Background The risk of venous thromboembolism is high after total hip arthroplasty and could persist after hospital discharge. Our aim was to compare... 
Internal Medicine | WEIGHT HEPARIN-PROPHYLAXIS | MEDICINE, GENERAL & INTERNAL | PLACEBO | FACTOR-XA INHIBITOR | ORTHOPEDIC-SURGERY | KNEE REPLACEMENT | BAY-59-7939 | THROMBOSIS | PROLONGED THROMBOPROPHYLAXIS | TIME-COURSE | DALTEPARIN | Thiophenes - therapeutic use | Double-Blind Method | Drug Administration Schedule | Thiophenes - adverse effects | Humans | Middle Aged | Morpholines - administration & dosage | Arthroplasty, Replacement, Hip | Male | Thiophenes - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Fibrinolytic Agents - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Fibrinolytic Agents - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Fibrinolytic Agents - administration & dosage | Morpholines - adverse effects | Morpholines - therapeutic use | Health care | Medical imaging | Hospitals | Protease inhibitors | Surgery | Tomography | Joint surgery | Drug therapy | Patients | Veins & arteries | Index Medicus | Abridged Index Medicus | Thiophenes/administration & dosage/adverse effects/therapeutic use | use | Arthroplasty | Replacement | Venous Thromboembolism/prevention & control | Morpholines/administration & dosage/adverse effects/therapeutic use | Kirurgi | Hip | 80 and over | Enoxaparin/administration & dosage/adverse effects/therapeutic use | Fibrinolytic Agents/administration & dosage/adverse effects/therapeutic
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2012, Volume 366, Issue 1, pp. 9 - 19
... in such patients has been limited by challenges associated with drug administration and the risk of bleeding. Likewise, treatment with the factor IIa inhibitor ximelagatran... 
ENOXAPARIN | MEDICINE, GENERAL & INTERNAL | PLACEBO | EVENTS | MYOCARDIAL-INFARCTION | SAFETY | DOUBLE-BLIND | THROMBOPROPHYLAXIS | APIXABAN | FACTOR XA INHIBITOR | ANTIPLATELET THERAPY | Thiophenes - therapeutic use | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Thiophenes - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Hemorrhage - mortality | Male | Secondary Prevention | Thiophenes - administration & dosage | Incidence | Rivaroxaban | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Morpholines - adverse effects | Morpholines - therapeutic use | Double-Blind Method | Drug Administration Schedule | Morpholines - administration & dosage | Kaplan-Meier Estimate | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Acute Coronary Syndrome - drug therapy | Intracranial Hemorrhages - chemically induced | Aged | Hemorrhage - chemically induced | Drugs | Dose-response relationship (Biochemistry) | Dosage and administration | Product/Service Evaluations | Drug therapy | Coronary heart disease | Myocardial infarction | Cerebral infarction | Anticoagulants | Heart attacks | Arteriosclerosis | Coronary artery | Cardiovascular disease | Death | Angina pectoris | Hemorrhage | Thrombosis | Bleeding
Journal Article
Stroke (1970), ISSN 1524-4628, 2013, Volume 44, Issue 6, pp. 1676 - 1681
Background and Purpose-To estimate the cost-effectiveness of stroke prevention in patients with nonvalvular atrial fibrillation by using novel oral... 
Intracranial hemorrhage | Stroke | Anticoagulation | Markov model | Cost-effectiveness | Atrial fibrillation | cost-effectiveness | ANTICOAGULATION CONTROL | QUALITY | anticoagulation | stroke | ASPIRIN | CLINICAL NEUROLOGY | PROPHYLAXIS | atrial fibrillation | HEART-DISEASE | BENEFIT | THERAPY | intracranial hemorrhage | SCORES | PERIPHERAL VASCULAR DISEASE | UPDATE | UTILITY | Thiophenes - therapeutic use | Markov Chains | Pyrazoles - therapeutic use | Anticoagulants - administration & dosage | United States | Humans | Anticoagulants - economics | Thiophenes - administration & dosage | Warfarin - economics | Benzimidazoles - economics | Dabigatran | Morpholines - economics | Warfarin - administration & dosage | Warfarin - therapeutic use | Dose-Response Relationship, Drug | Pyridones - administration & dosage | Rivaroxaban | Benzimidazoles - administration & dosage | beta-Alanine - economics | Stroke - epidemiology | Thiophenes - economics | Pyridones - economics | beta-Alanine - analogs & derivatives | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Quality-Adjusted Life Years | Stroke - prevention & control | Administration, Oral | Morpholines - administration & dosage | Risk Factors | Atrial Fibrillation - complications | beta-Alanine - administration & dosage | beta-Alanine - therapeutic use | Anticoagulants - therapeutic use | Models, Statistical | Pyrazoles - economics | Pyrazoles - administration & dosage | Cost-Benefit Analysis | Aged | Pyridones - therapeutic use | Cohort Studies
Journal Article
Circulation, ISSN 0009-7322, 12/2010, Volume 122, Issue 24, pp. 2619 - 2633
proton pump inhibitors | antiplatelet drugs | gastrointestinal hemorrhage | platelet aggregation inhibitors | aspirin | thienopyridine | AHA Scientific Statements | CYTOCHROME-P450 | CARDIAC & CARDIOVASCULAR SYSTEMS | MYOCARDIAL-INFARCTION | ACID SUPPRESSION | PERCUTANEOUS CORONARY INTERVENTION | CLOPIDOGREL | LOW-DOSE ASPIRIN | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | DISEASE | PERIPHERAL VASCULAR DISEASE | PRASUGREL | PEPTIC-ULCERS | Piperazines - administration & dosage | Prasugrel Hydrochloride | Purinergic P2Y Receptor Antagonists - administration & dosage | Thiophenes - adverse effects | Cardiovascular Diseases - drug therapy | Humans | Thienopyridines - adverse effects | Thienopyridines - metabolism | Piperazines - metabolism | Thiophenes - metabolism | Thiophenes - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - metabolism | Histamine H2 Antagonists - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Aspirin - adverse effects | Aspirin - metabolism | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - metabolism | Ticlopidine - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Platelet Aggregation Inhibitors - metabolism | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Thienopyridines - administration & dosage | Risk Factors | Histamine H2 Antagonists - adverse effects | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Aryl Hydrocarbon Hydroxylases - metabolism | Gastrointestinal Hemorrhage - chemically induced | Gastrointestinal Hemorrhage - prevention & control | Histamine H2 Antagonists - metabolism | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Cytochrome P-450 CYP2C19 | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Proton Pump Inhibitors - metabolism
Journal Article